x

Posted 12 January, 2024

Bioventus Inc. appointed Mr. Bihl as new CEO

Nasdaq:BVS appointed new Chief Executive Officer Mr. Bihl in a 8-K filed on 12 January, 2024.


  The Equity Awards, which were granted in connection with Mr. Bihl's appointment as the Company's Interim President and Chief Executive Officer in April 2023, were to vest in April 2024, subject to continued employment, and provided for acceleration of vesting at the discretion of the Board and/or the Board's Compensation Committee.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Bioventus Inc.
Health Care/Life Sciences • Medical Equipment/Supplies
Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.
Market Cap
$406M
View Company Details
Bioventus Inc. by TradingView
Relevant filing section
Item 5.02. 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


On January 9, 2024, the Board of Directors (the "Board") of Bioventus Inc. (the "Company") approved the acceleration of vesting of all of the outstanding and unvested equity awards (the "Equity Awards") of Anthony P. Bihl III, the Company's then Interim President and Chief Executive Officer and a director on the Board, effective immediately. The Equity Awards, which were granted in connection with Mr. Bihl's appointment as the Company's Interim President and Chief Executive Officer in April 2023, were to vest in April 2024, subject to continued employment, and provided for acceleration of vesting at the discretion of the Board and/or the Board's Compensation Committee. As previously reported, Robert E. Claypoole succeeded Mr. Bihl as President and Chief Executive Officer of the Company on January 10, 2024. The Board's decision to accelerate the outstanding and unvested Equity Awards pursuant to their terms was based on Mr. Bihl's performance and contributions to the Company.